Literature DB >> 891094

Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol.

N L Benowitz, R T Jones.   

Abstract

Delta-9-tetrahydrocannabinol (THC) has been reported to inhibit drug metabolism in animals. Twenty-two hospitalized healthy volunteer subjects received THC, 60 to 180 mg/day in divided doses for 14 days. Body weight increased and plasma proteins decreased in all subjects, which is consistent with previously reported plasma volume expansion. Total bilirubin was significantly lower, while other liver function tests remained normal. A within-subject comparison of the pharmacokinetics of antipyrine, pentobarbital, or ethanol given before, during, and after THC was performed. Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8. Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2. Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07. The effect of THC on disappearance rate of these drugs appeared to be due to a combination of: (1) increased distribution volume, due in part to expansion of extracellular fluid volume noted during THC ingestion, and (2) diminished metabolic clearance. THC also delayed absorption of pentobarbital and ethanol in several subjects. This is consistent with THC effects of slowing intestinal motility in animals. The effects of THC on absorption and drug elimination must be considered in evaluating interactions with other drugs.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 891094     DOI: 10.1002/cpt1977223259

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Research review. Interactions between environmental chemicals and drug biotransformation in man.

Authors:  A P Alvares
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

Review 2.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 4.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  Antipyrine kinetics in cannabis smokers.

Authors:  R Uppal; S K Garg; P R Sharma; V K Varma; R R Chaudhury
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

6.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 7.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

8.  Effect of chloroquine and primaquine on antipyrine metabolism.

Authors:  D J Back; H S Purba; B K Park; S A Ward; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

9.  Delta-9-tetrahydrocannabinol and gastric emptying.

Authors:  D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

10.  Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.

Authors:  J E Lindgren; A Ohlsson; S Agurell; L Hollister; H Gillespie
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.